Apatinib with adebrelimab and EC chemo for first-line extensive small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of three drugs (apatinib, adebrelimab, and EC chemotherapy) as the first treatment for extensive-stage small cell lung cancer that has spread. The goal is to see if this combination works better than standard treatments alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer (cancer that has spread beyond one lung)
- You should not have had any previous chemotherapy or other treatment for this cancer
- You need to be between 18 and 75 years old
- You must be able to care for yourself and be out of bed more than half the day (ECOG score 0 or 1)
- Your cancer must have at least one measurable tumor that can be seen on scans
- Your major organs (like bone marrow, liver, kidneys) need to work well enough based on blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, liposomal irinotecan and apatinib, for people with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after first or second line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
This trial tests a combination of irinotecan liposome (a chemotherapy) or etoposide with adebrelimab (an immunotherapy) and carboplatin for people with extensive-stage small cell lung cancer who haven't had prior treatment. It aims to see if these combinations are safe and effective.
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
This trial tests giving a combination of two medications, adebrelimab (an immunotherapy) and apatinib (a targeted therapy), before surgery for people with stage II or III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug (Adebelimab) combined with standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination works better than chemo alone.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.